NCT04588428View on ClinicalTrials.gov

Safety, Tolerability and Immunogenicity of INO-4700 for MERS-CoV in Healthy Volunteers

PHASE2CompletedINTERVENTIONAL
Enrollment

192

Participants

Timeline

Start Date

June 21, 2021

Primary Completion Date

January 19, 2023

Study Completion Date

January 19, 2023

Conditions
Middle East Respiratory Syndrome Coronavirus (MERS-CoV)
Interventions
DRUG

INO-4700

INO-4700 was administered ID.

DRUG

Placebo

Sterile saline sodium citrate (SSC) buffer (SSC-0001) was administered ID.

DEVICE

CELLECTRA™ 2000

EP using the CELLECTRA™ 2000 device was administered following ID drug administration

Trial Locations (6)

20200

Kenya Medical Research Institute (KEMRI)/Walter Reed Project (WRP), Kericho

21110

Clinical Research Center, Irbid Specialty Hospital (CRC/ISH), Irbid

22110

Pharmaceutical Research Center / Jordan University of Science and Technology, Irbid

40100

Ahero Clincal Trials Unit, Kisumu

Unknown

American University of Beirut Medical Center, Beirut

Hammoud Hospital University Medical Center, Saida

Sponsors
All Listed Sponsors
collaborator

Coalition for Epidemic Preparedness Innovations

OTHER

lead

Inovio Pharmaceuticals

INDUSTRY

NCT04588428 - Safety, Tolerability and Immunogenicity of INO-4700 for MERS-CoV in Healthy Volunteers | Biotech Hunter | Biotech Hunter